regn

Putting Biotech Stocks Under the Microscope – Barron's – Barrons.com

In 1996, fresh out Harvard, Rajiv Kaul went to work as an analyst covering biotechnology at Fidelity Investments. At the time, the sector was still considered a risky niche—the perfect project for the new guy. “Biotech was viewed like a lottery ticket,” says Kaul, 41. “It was something conventional investors shied away from.”
Where others saw uncertainty, Kaul saw possibility. After […]

Putting Biotech Stocks Under the Microscope – Barron's

In 1996, fresh out Harvard, Rajiv Kaul went to work as an analyst covering biotechnology at Fidelity Investments. At the time, the sector was still considered a risky niche—the perfect project for the new guy. “Biotech was viewed like a lottery ticket,” says Kaul, 41. “It was something conventional investors shied away from.”
Where others saw uncertainty, Kaul saw possibility. After […]